BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE AS PRIMARY INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA SIGNIFICANTLY DECREASES BONE RESORPTION WHILE SPARING BONE FORMATION AS COMPARED TO THALIDOMIDE-DEXAMETHASONE

被引：0
|
作者：
Tosi, P. [1 ]
Zamagni, E. [1 ]
Tacchetti, P. [1 ]
Perrone, G. [1 ]
Ceccolini, M. [1 ]
Brioli, A. [1 ]
Pallotti, M. [1 ]
Pantani, L. [1 ]
Petrucci, A. [1 ]
Baccarani, M. [1 ]
Cavo, M. [1 ]
机构：
[1] Seragnoli Inst Hematol & Med Oncol, Bologna, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0659
引用
收藏
页码：265 / 265
页数：1
相关论文
共 50 条
  • [41] Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
    Cavo, Michele
    Tacchetti, Paola
    Patriarca, Francesca
    Petrucci, Maria Teresa
    Pantani, Lucia
    Galli, Monica
    Di Raimondo, Francesco
    Crippa, Claudia
    Zamagni, Elena
    Palumbo, Antonio
    Offidani, Massimo
    Corradini, Paolo
    Narni, Franco
    Spadano, Antonio
    Pescosta, Norbert
    Deliliers, Giorgio Lambertenghi
    Ledda, Antonio
    Cellini, Claudia
    Caravita, Tommaso
    Tosi, Patrizia
    Baccarani, Michele
    LANCET, 2010, 376 (9758): : 2075 - 2085
  • [42] Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia
    Cesar Solano, Julio
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S248 - S248
  • [43] Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
    Sonneveld, Pieter
    Asselbergs, Emilie
    Zweegman, Sonja
    van der Holt, Bronno
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    Broyl, Annemiek
    de Weerdt, Okke
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorstl, Henk
    BLOOD, 2015, 125 (03) : 449 - 456
  • [44] Prediction of response to primary therapy with thalidomide-dexamethasone(Thal-DEX) for newly diagnosed multiple myeloma by gene expression profiling (GEP)
    Terragna, C.
    Renzulli, M.
    Remondini, D.
    Tagliafico, E.
    Roncaglia, E.
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A. M.
    Martinelli, G.
    Baccarani, M.
    Cavo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 177 - 177
  • [45] Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by Gene Expression Profiling (GEP)
    Terragna, C.
    Renzulli, M.
    Remondini, D.
    Tagliafico, E.
    Roncaglia, E.
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A.
    Pallotti, M. C.
    Martinelli, G.
    Baccarani, M.
    Cavo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 138 - 138
  • [46] Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Sauer, Sandra
    Kriegsmann, Katharina
    Nientiedt, Cathleen
    Schmitt, Anita
    Mueller-Tidow, Carsten
    Raab, Marc-Steffen
    Kauer, Joseph
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2023, 50 (05) : 371 - 380
  • [47] Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients With Symptomatic Multiple Myeloma A Retrospective Study
    Kaufman, Jonathan L.
    Nooka, Ajay
    Vrana, Mark
    Gleason, Charise
    Heffner, L. Thompson
    Lonial, Sagar
    CANCER, 2010, 116 (13) : 3143 - 3151
  • [48] Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes
    Tacchetti, Paola
    Dozza, Luca
    Di Raimondo, Francesco
    Crippa, Claudia
    Zamagni, Elena
    Bringhen, Sara
    Pantani, Lucia
    Offidani, Massimo
    Montefusco, Vittorio
    Narni, Franco
    Mancuso, Katia
    Cellini, Claudia
    Spadano, Antonio
    Pescosta, Norbert
    Baldini, Luca
    Terragna, Carolina
    Nozzoli, Chiara
    Zambello, Renato
    Derudas, Daniele
    Ballanti, Stelvio
    Cavo, Michele
    BLOOD, 2018, 132
  • [49] Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
    Rosinol, Laura
    Hebraud, Benjamin
    Oriol, Albert
    Colin, Anne-Laurene
    Tamayo, Rafael Rios
    Hulin, Cyrille
    Blanchard, Maria Jesus
    Caillot, Denis
    Sureda, Anna
    Hernandez, Miguel Teodoro
    Arnulf, Bertrand
    Mateos, Maria-Victoria
    Macro, Margaret
    San-Miguel, Jesus
    Belhadj, Karim
    Lahuerta, Juan Jose
    Garelik, M. Brigid
    Blade, Joan
    Moreau, Philippe
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Huston, Alissa
    Brown, Jason
    Roodman, G. David
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (12) : 1616 - 1616
12345